Essential Thrombocythemia is best described as

Essential Thrombocythemia is best described as

• A. A stem cell disorder causing a critical increase in platelet counts
• B. An autoimmune disorder
• C. A chronic infection
• D. A vitamin deficiency

Answer: (A)

Essential thrombocythemia is a myeloproliferative neoplasm driven by a mutated hematopoietic stem cell that causes clonal, uncontrolled megakaryocyte proliferation and a sustained, marked rise in platelets. Because the problem originates in the bone marrow as a primary clonal process, the high platelet count is not a reaction to another condition. This distinguishes it from autoimmune disorders, chronic infections, or vitamin deficiencies, which produce thrombocytosis only as secondary, reactive processes. In ET, the overproduction of platelets is due to a stem cell–level abnormality (often with mutations such as JAK2, CALR, or MPL) and carries a risk of thrombosis and bleeding, guiding treatment to reduce thrombotic risk.

Essential thrombocythemia is a myeloproliferative neoplasm driven by a mutated hematopoietic stem cell that causes clonal, uncontrolled megakaryocyte proliferation and a sustained, marked rise in platelets. Because the problem originates in the bone marrow as a primary clonal process, the high platelet count is not a reaction to another condition. This distinguishes it from autoimmune disorders, chronic infections, or vitamin deficiencies, which produce thrombocytosis only as secondary, reactive processes. In ET, the overproduction of platelets is due to a stem cell–level abnormality (often with mutations such as JAK2, CALR, or MPL) and carries a risk of thrombosis and bleeding, guiding treatment to reduce thrombotic risk.